CA2549550A1 - Botulinum toxin therapy for skin disorders - Google Patents

Botulinum toxin therapy for skin disorders Download PDF

Info

Publication number
CA2549550A1
CA2549550A1 CA002549550A CA2549550A CA2549550A1 CA 2549550 A1 CA2549550 A1 CA 2549550A1 CA 002549550 A CA002549550 A CA 002549550A CA 2549550 A CA2549550 A CA 2549550A CA 2549550 A1 CA2549550 A1 CA 2549550A1
Authority
CA
Canada
Prior art keywords
botulinum toxin
skin disorder
use according
skin disorders
wart
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002549550A
Other languages
French (fr)
Other versions
CA2549550C (en
Inventor
Eric R. First
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2549550A1 publication Critical patent/CA2549550A1/en
Application granted granted Critical
Publication of CA2549550C publication Critical patent/CA2549550C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Methods for treating skin disorders by local administration of a Clostridial toxin, such as a botulinum toxin, to a patient with a skin disorder, such as a wart, corn, callus or bunion.

Claims (11)

1. Use of a botulinum toxin for the manufacture of a medicament for treating a skin disorder.
2. The use according to claim 1 wherein the botulinum toxin is a botulinum toxin type A, B, C, D, E, F or G.
3. The use according to claim 1 wherein the botulinum toxin is a botulinum toxin type A.
4. The use according to claim 1 wherein the botulinum toxin is administered in an amount of between about 1 unit and about 3,000 units.
5. The use according to claim 1 wherein the administration is by topical or subcutaneous administration of the botulinum toxin.
6. Use of a botulinum toxin for the manufacture of a medicament for treating a skin disorder by locally administering between 1 unit and 3000 units of a botulinum toxin to a skin disorder of a patient.
7. The use according to 6, wherein the skin disorder is a wart, corn, callus or bunion.
8. The use according to claim 6 wherein the skin disorder is treated by reducing a pain associated with the skin disorder.
9. The use according to claim 6 wherein the skin disorder is treated by reducing an inflammation associated with the skin disorder.
10. The use according to claim 6 wherein the skin disorder is treated by reducing a size of the skin disorder.
11. Use of a botulinum toxin for the manufacture of a medicament for treating a wart by administering an effective amount of the botulinum toxin to the wart.
CA2549550A 2003-12-09 2004-12-08 Botulinum toxin therapy for skin disorders Expired - Fee Related CA2549550C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/731,973 2003-12-09
US10/731,973 US8048423B2 (en) 2003-12-09 2003-12-09 Botulinum toxin therapy for skin disorders
PCT/US2004/041327 WO2005056050A1 (en) 2003-12-09 2004-12-08 Botulinum toxin therapy for skin disorders

Publications (2)

Publication Number Publication Date
CA2549550A1 true CA2549550A1 (en) 2005-06-23
CA2549550C CA2549550C (en) 2012-07-17

Family

ID=34634457

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2549550A Expired - Fee Related CA2549550C (en) 2003-12-09 2004-12-08 Botulinum toxin therapy for skin disorders

Country Status (10)

Country Link
US (1) US8048423B2 (en)
EP (2) EP1691830B1 (en)
JP (1) JP4937758B2 (en)
AT (2) ATE369874T1 (en)
AU (1) AU2004296870B2 (en)
BR (1) BRPI0417493B8 (en)
CA (1) CA2549550C (en)
DE (2) DE602004023886D1 (en)
ES (2) ES2335310T3 (en)
WO (1) WO2005056050A1 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8871224B2 (en) 2003-12-09 2014-10-28 Allergan, Inc. Botulinum toxin therapy for skin disorders
US20080008777A1 (en) * 2004-02-12 2008-01-10 Philip Radovic Methods of treating a bunion
US7276244B2 (en) * 2004-02-12 2007-10-02 Philip Radovic Methods of treating abnormalities of the first metatarsophalangeal joint of the foot
US8497081B2 (en) 2004-02-24 2013-07-30 Allergan, Inc. Botulinum toxin screening assays
EP1718756B1 (en) * 2004-02-24 2011-11-16 Allergan, Inc. Botulinum toxin screening assays
US20050191321A1 (en) 2004-02-26 2005-09-01 Allergan, Inc. Methods for treating headache
US20100266638A1 (en) 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US20050220821A1 (en) * 2004-03-31 2005-10-06 Allergan, Inc. Pressure sore treatment
US20050220734A1 (en) * 2004-04-02 2005-10-06 Allergan, Inc. Therapy for melanin related afflictions
US7922983B2 (en) * 2005-07-28 2011-04-12 Kimberly-Clark Worldwide, Inc. Sterilization wrap with additional strength sheet
US20060024331A1 (en) * 2004-08-02 2006-02-02 Ester Fernandez-Salas Toxin compounds with enhanced membrane translocation characteristics
ES2373963T3 (en) * 2004-09-23 2012-02-10 Toxcure, Inc. TREATMENT OF NEOPLASMS WITH NEUROTOXINE.
US8343929B2 (en) 2004-09-23 2013-01-01 Toxcure, Inc. Treating neoplasms with neurotoxin
EP1799254A1 (en) * 2004-09-27 2007-06-27 Merz Pharma GmbH & Co.KGaA Clostridial neurotoxins for use in tissue healing
US7655244B2 (en) 2005-02-01 2010-02-02 Allergan, Inc. Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions
US7749515B2 (en) 2005-02-01 2010-07-06 Allergan, Inc. Targeted delivery of botulinum toxin to the sphenopalatine ganglion
US7419675B2 (en) * 2005-05-26 2008-09-02 Allergan, Inc. Method for treating peritoneal adhesions
US20070128226A1 (en) * 2005-12-01 2007-06-07 Philip Radovic Methods of treating pain associated with abnormalities of the first metatarsophalangeal joint of the foot
US7824694B2 (en) * 2006-01-12 2010-11-02 Allergan, Inc. Methods for enhancing therapeutic effects of a neurotoxin
CN101074935B (en) * 2006-05-19 2011-03-23 清华大学 Detector array and its apparatus
US8870876B2 (en) 2009-02-13 2014-10-28 Tarsus Medical Inc. Methods and devices for treating hallux valgus
US8277459B2 (en) 2009-09-25 2012-10-02 Tarsus Medical Inc. Methods and devices for treating a structural bone and joint deformity
US8652141B2 (en) 2010-01-21 2014-02-18 Tarsus Medical Inc. Methods and devices for treating hallux valgus
US8696719B2 (en) 2010-06-03 2014-04-15 Tarsus Medical Inc. Methods and devices for treating hallux valgus
PT2661276T (en) * 2011-01-07 2017-10-06 Revance Therapeutics Inc Topical composition comprising botulinum toxin and a dye
ES2424294B1 (en) 2012-03-22 2014-07-21 Lipotec, S.A. Exopolysaccharide for the treatment and / or care of skin, mucous membranes, hair and / or nails
EP2649983A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (II)
EP2649985A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (III)
ES2660901T3 (en) 2012-04-13 2018-03-26 Lubrizol Advanced Materials, Inc. Compounds that inhibit neuronal exocytosis (II)
EP2649984A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis
US9259343B2 (en) 2012-07-06 2016-02-16 Newman Technologies LLC Device for mitigating plantar fasciitis
US20160045423A1 (en) 2013-03-22 2016-02-18 Lipotec S.A. Exopolysaccharide for the treatment and/or care of the skin, mucous membranes and/or nails
JP2020510100A (en) 2017-03-13 2020-04-02 フィリップ アンドリュー ラドヴィッチ Neuromuscular toxin for use in treating abnormalities of the first metatarsophalangeal joint of the foot
WO2018222652A1 (en) * 2017-05-31 2018-12-06 Allergan, Inc. Botulinum neurotoxin for treatment of disorders associated with melanocyte hyperactivity and/or excess melanin

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5562907A (en) * 1993-05-14 1996-10-08 Arnon; Stephen S. Method to prevent side-effects and insensitivity to the therapeutic uses of toxins
US5437291A (en) * 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
JP3066079B2 (en) * 1994-05-09 2000-07-17 ビンダー，ウィリアム，ジェイ． How to reduce headaches
US5670484A (en) * 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
GB9508204D0 (en) * 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
ATE216589T1 (en) * 1996-11-27 2002-05-15 William J Binder NEUROTOXINS FOR THE TREATMENT OF SKIN DISEASES IN MAMMALS
US6063768A (en) * 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
BR9914891A (en) * 1998-10-27 2001-07-17 Mayo Foundation Wound healing improvement processes
US6477410B1 (en) * 2000-05-31 2002-11-05 Biophoretic Therapeutic Systems, Llc Electrokinetic delivery of medicaments
US6265379B1 (en) * 1999-10-13 2001-07-24 Allergan Sales, Inc. Method for treating otic disorders
US7838007B2 (en) * 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating mammary gland disorders
US6139845A (en) * 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US6464986B1 (en) * 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6299893B1 (en) * 2000-04-17 2001-10-09 Marvin Schwartz Method to reduce hair loss and stimulate hair regrowth
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US6423319B1 (en) * 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
KR100602308B1 (en) 2001-07-27 2006-07-18 더 보드 오브 수퍼바이저스 오브 루이지애나 스테이트 유니버시티 앤드 애그리컬춰럴 앤드 미케니칼 칼리지 Botulinum toxin in the treatment or prevention of acne
DE10146647A1 (en) * 2001-09-21 2003-04-24 Marc Heckmann Medicines for the prophylaxis and therapy of bromhidrosis
US6945952B2 (en) * 2002-06-25 2005-09-20 Theraject, Inc. Solid solution perforator for drug delivery and other applications
WO2004000389A2 (en) * 2002-06-25 2003-12-31 Sung-Yun Kwon Rapidly dissolving micro-perforator for drug delivery and other applications
US6776991B2 (en) * 2002-06-26 2004-08-17 Allergan, Inc. Methods for treating priapism
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
US20060153876A1 (en) * 2003-02-24 2006-07-13 Ira Sanders Cell membrane translocation of regulated snare inhibitors, compositions therefor, and methods for treatment of disease
US7335367B2 (en) * 2003-03-06 2008-02-26 Botulinum Toxin Research Associates, Inc. Treatment of chronic chalazion and hordeolum with botulinum toxin

Also Published As

Publication number Publication date
ES2335310T3 (en) 2010-03-24
DE602004008329D1 (en) 2007-09-27
US8048423B2 (en) 2011-11-01
ATE446769T1 (en) 2009-11-15
AU2004296870B2 (en) 2010-05-20
AU2004296870A1 (en) 2005-06-23
JP2007513964A (en) 2007-05-31
DE602004023886D1 (en) 2009-12-10
ES2289591T3 (en) 2008-02-01
US20050123567A1 (en) 2005-06-09
EP1820510A1 (en) 2007-08-22
CA2549550C (en) 2012-07-17
BRPI0417493B1 (en) 2018-11-13
DE602004008329T2 (en) 2008-05-08
JP4937758B2 (en) 2012-05-23
EP1691830A1 (en) 2006-08-23
EP1691830B1 (en) 2007-08-15
BRPI0417493B8 (en) 2021-05-25
EP1820510B1 (en) 2009-10-28
BRPI0417493A (en) 2007-05-29
ATE369874T1 (en) 2007-09-15
WO2005056050A1 (en) 2005-06-23

Similar Documents

Publication Publication Date Title
CA2549550A1 (en) Botulinum toxin therapy for skin disorders
Leggit Acute and chronic paronychia
IL171607A (en) Use of a botulinum toxin for the preparation of a medicament for treating sinus headache
Ozlugedik et al. Can postoperative pains following tonsillectomy be relieved by honey?: A prospective, randomized, placebo controlled preliminary study
ES2164097T3 (en) USE OF TOPIC ANESTHETICS FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF BRONCHIAL ASTHMA.
MX337511B (en) Medicaments and methods for treating headache.
Han et al. Subdermal minimal surgery with hyaluronic acid as an effective treatment for neck wrinkles
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
Paquette et al. Short-contact topical tretinoin therapy to stimulate granulation tissue in chronic wounds
WO2004073622A3 (en) Novel therapeutic method and compositions for topical administration
Carneiro et al. Topical phenytoin versus EUSOL in the treatment of non-malignant chronic leg ulcers
GR3034338T3 (en) Therapeutic system for treating psoriasis
CA2561588A1 (en) Pressure sore treatment
Gallagher et al. A retrospective health economic analysis of a stable hypochlorous acid preserved wound cleanser versus 0.9% saline solution as instillation for negative-pressure wound therapy in severe and infected wounds
Knight Medical management of pressure sores
US10232004B2 (en) Pharmaceutical composition based on Centella asiatica (Hydrocotyle asiatica L.) for the treatment of lower limb ulcers
US20030092682A1 (en) Use of doxycycline for treatment of certain skin and mouth ailments
Ji et al. Sanguis draconis (Daemonorops draco): a case report of treating a chronic pressure ulcer with tunneling
CN1843366A (en) Burn-treating liquid
RU2814360C1 (en) Method of treating phymatous subtype of rosacea by points
Miserya Pain Management in Dermatology
Houque et al. A Case Report of Acne Vulgaris: Treated by Combination with Acupuncture
Ahn et al. Effect of the Combination Treatment of Injection to Scar and Intercostal Nerve Block for Patients with Post-Zoster Neuralgia on the Trunk
Baldwin et al. Treatment of a sacral pressure ulcer and extensive hyperkeratosis with OPAL A filtrate and cream: A case study
Chaudhary et al. Honey ‘The Life Saviour’in Necrotising Fascitis: A Case Report

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20211208